In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Tango Therapeutics Inc’s stock clocked out at $7.87, up 3.28% from its previous closing price of $7.62. In other words, the price has increased by $3.28 from its previous closing price. On the day, 3.69 million shares were traded. TNGX stock price reached its highest trading level at $8.04 during the session, while it also had its lowest trading level at $7.65.
Ratios:
To gain a deeper understanding of TNGX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The Stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned. The Stock a target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 16 ’25 when Third Rock Ventures IV, L.P. sold 363,541 shares for $7.04 per share. The transaction valued at 2,559,329 led to the insider holds 14,363,975 shares of the business.
Third Rock Ventures IV, L.P. bought 363,541 shares of TNGX for $2,672,026 on Sep 16 ’25. On Sep 05 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 642,906 shares for $7.00 each. As a result, the insider received 4,500,342 and left with 14,813,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 875618112 and an Enterprise Value of 729841152. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 36.03 while its Price-to-Book (P/B) ratio in mrq is 6.47. Its current Enterprise Value per Revenue stands at 30.04 whereas that against EBITDA is -4.715.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.65, which has changed by -0.051807225 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $8.98, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of. The Stock is 17.22%, while the 200-Day Moving Average is calculated to be 112.39%.
Shares Statistics:
It appears that TNGX traded 2.04M shares on average per day over the past three months and 2585210 shares per day over the past ten days. A total of 110.87M shares are outstanding, with a floating share count of 65.98M. Insiders hold about 40.69% of the company’s shares, while institutions hold 73.26% stake in the company. Shares short for TNGX as of 1756425600 were 25400631 with a Short Ratio of 12.45, compared to 1753920000 on 22475890. Therefore, it implies a Short% of Shares Outstanding of 25400631 and a Short% of Float of 27.389999999999997.
Earnings Estimates
A detailed examination of Tango Therapeutics Inc (TNGX) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $41.34M. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M
